XORTX Therapeutics Inc. — FY2021 Form 20-F Summary
Reporting period: Year ended December 31, 2021; comparative financial information is primarily for FY2020. This is an annual report, not a quarterly filing. Financial statements are prepared under IFRS as issued by the IASB, in Canadian dollars unless noted otherwise.
Business context
XORTX is a clinical-stage biotechnology company developing uric-acid-lowering therapies for kidney disease. Its lead programs are XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for acute kidney injury (AKI) associated with COVID-19, and XRx-225 for type 2 diabetic nephropathy. The company had no approved products and no product-sales revenue.
Financial performance and position
| Metric (C$ unless stated) | FY2021 / Dec. 31, 2021 | FY2020 / Dec. 31, 2020 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Net loss | $1.652 million | $1.285 million |
| Loss per share, basic and diluted | $0.17 | $0.19 |
| Research and development expense | $853,124 | $277,455 |
| Cash and cash equivalents | $18.851 million | $171,271 |
| Net cash used in operating activities | $6.063 million | $728,401 |
| Total assets | $22.036 million | $2.290 million |
| Total liabilities | $5.298 million | $1.034 million |
| Shareholders’ equity | $16.738 million | $1.256 million |
- Revenue and gross margin are not meaningful for this pre-commercial company; the filing reports no product-sales revenue.
- Current assets were $20.173 million and current liabilities were $700,999, implying working capital of approximately $19.472 million. The company reported no conventional borrowings in the financial statements; liabilities included accounts payable and a $4.597 million derivative warrant liability.
- The net loss increased by about 29% from FY2020. Operating expenses rose, especially R&D, consulting and investor-relations costs. Loss per share decreased despite the higher net loss, alongside a larger weighted-average share count.
- FY2021 net loss included a $3.300 million fair-value gain on derivative warrant liabilities and a $326,751 foreign-exchange gain, partly offset by $1.624 million of warrant-related transaction costs. These items materially affect comparison of reported loss with operating cash use.
- Financing activities provided net cash of $24.457 million, principally reflecting equity financing. The company completed a U.S. public offering in October 2021 and a partial over-allotment sale in November. It reported approximately $3.0 million of offering proceeds used by year-end; the remaining proceeds were intended for operations and development, with planned allocations of 29% to XRx-008, 70% to XRx-101 and 1% to XRx-225.
Material changes and unusual items
- Cash increased from $171,271 to $18.851 million, largely following FY2021 equity financings, including the U.S. offering.
- Common shares outstanding increased from 6.915 million at year-end 2020 to 12.990 million at year-end 2021. The company also completed a 1-for-11.74 share consolidation in September 2021 and began Nasdaq trading in October.
- The balance sheet includes a $4.597 million derivative warrant liability. Warrant accounting and fair-value movements contributed significantly to reported FY2021 results; the liability is non-cash and the filing says it is expected to convert to equity or expire.
- Prepaid expenses rose to $1.271 million. A $1.606 million payment to Prevail for future regulatory and clinical-trial programs was reclassified as non-current.
- Auditors issued an unqualified opinion on the IFRS financial statements and reported no critical audit matters. The auditor did not opine on internal control over financial reporting; the company cited an exemption for newly public companies. Management concluded disclosure controls were effective at year-end.
Outlook, commentary and risks
- Management stated that cash and net proceeds from the U.S. offering were expected to fund advancement of its programs, but the filing gives no definitive cash-runway estimate. It also says substantial additional funding will be required and may not be available on acceptable terms.
- Plans disclosed for 2022 included XRx-008 and XRx-101 formulation and pharmacokinetic bridging studies, an XRx-008 IND submission, orphan-drug designation work and preparation for an ADPKD registration trial. The proposed XRx-008 Phase 3 trial was targeted for the second half of 2022, subject to FDA discussions and a special protocol assessment. Management discussed a potential U.S. XRx-008 NDA filing in 2025. These are forward-looking plans, not assured milestones.
- XRx-225 remained at the nonclinical stage. The filing describes further preclinical work before possible clinical testing.
- Key risks include clinical-trial failure or delay, regulatory uncertainty—particularly eligibility for the 505(b)(2) pathway—patient recruitment, manufacturing and reliance on third parties, intellectual-property challenges, competition, reimbursement and pricing, and the need for further capital. COVID-19-related disruption and broader market conditions could also affect operations and financing.
- The company had no internal sales or manufacturing infrastructure and relied on contract manufacturers, CROs and research partners. It reported two full-time employees and 12 consultants at December 31, 2021.
- The company said it may have been a passive foreign investment company (PFIC) for U.S. tax purposes in 2021 and may be one in 2022 or later years, creating potential tax and reporting consequences for U.S. investors.
Important facts for investors to verify
- Review the audited statements and MD&A for cash burn, forecast assumptions and the company’s estimated funding needs; the filing does not provide a clear runway estimate.
- Check subsequent FDA interactions, IND status, bridging-study results and whether the proposed XRx-008 trial design and timing were achieved.
- Reconcile warrant terms and the $4.597 million derivative liability, including potential dilution from outstanding warrants, options and future financings.
- Assess whether the clinical, regulatory and commercial assumptions supporting XRx-008 and XRx-101 remain viable; neither program had an approved product or established product revenue.
- U.S. investors should confirm the company’s PFIC status and related tax-information availability with their tax advisers.